Press Releases Salarius Pharmaceuticals, Inc.

Equities

SLRX

US79400X3052

Market Closed - Nasdaq Other stock markets 02:00:00 16/05/2024 am IST			5-day change	1st Jan Change
0.458 ^USD	+0.64%		-5.99%	-29.54%

25/03	Wall Street Set to Open Modestly Lower Monday Ahead of Housing, Inflation Data	MT
25/03	Top Premarket Gainers	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Salarius: Q1 Earnings Snapshot	14/05	AQ
Salarius: Q4 Earnings Snapshot	23/03	AQ
Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	23/03	AQ
Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses	22/02	AQ
Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders	16/01	AQ
Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment	03/01	AQ
Chronic Myelomonocytic Leukaemia Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)	20/12	AQ
Salarius: Q3 Earnings Snapshot	10/11	AQ
Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program	07/11	AQ
Salarius: Q2 Earnings Snapshot	11/23/11	AQ
Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update	11/23/11	AQ
Salarius Pharmaceuticals Announces Plans to Explore Strategic Alternatives and Implement Measures to Extend its Resources	09/23/09	AQ
Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients	11/23/11	AQ
Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress	12/23/12	AQ
Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules	12/23/12	AQ
Salarius: Q1 Earnings Snapshot	11/23/11	AQ
Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update	11/23/11	AQ
FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals’ Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma	09/23/09	AQ
Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164	01/23/01	AQ
Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meeting	20/23/20	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Salarius Pharmaceuticals, Inc.

Equities

SLRX

US79400X3052

Press Releases

Filters